Blog
RSS FeedPosted by Michael Wonder on 26 Jul 2016
CADTH recommends reimbursement of Sunvepra
20 July 2016 - CADTH has recommended that asunaprevir (Sunvepra) be reimbursed in Canada. ...
Posted by Michael Wonder on 23 Mar 2016
CADTH calls for patient input on a submission from Gilead for sofosbuvir with velpatasvir
23 March 2016 - CADTH has received notice of a pending submission from Gileda for sofosbuvir with velpatasvir for the treatment ...
Posted by Michael Wonder on 07 Jan 2016
CADTH calls for patient input on submissions requesting advice on recent recommendations for new hepatitis C medicines
6 January 2016 - CADTH has received submissions requesting advice for Sovaldi, Harvoni, Holkira Pak & Daklinza. ...
Posted by Michael Wonder on 05 Jan 2016
Final CADTH reports on drugs for chronic hepatitis C infection
5 January 2016 - CADTH updated its previous therapeutic review examining the clinical and economic impact of new and existing drugs ...
Posted by Michael Wonder on 24 Sep 2015
CADTH recommends the reimbursement of four new products
24 September 2015 - The Canadian Drug Expert Committee (CDEC) of CADTH has recommended the reimbursement of the following products: ...
Posted by Michael Wonder on 23 Sep 2015
CADTH calls for patient input on a new submission from Merck
23 September 2015 - CADTH has received notice of a pending submission from Merck for grazoprevir with elbasvir for use by ...
Posted by Michael Wonder on 15 Sep 2015
CADTH calls for feedback on draft report on drugs for chronic hepatitis C infection
15 September 2015 - CADTH is pleased to invite all interested parties to provide feedback on draft recommendations for the CADTH ...